Blend is a biotechnology company with an innovative platform for creating novel medicines, including miniaturized biologic drug conjugates (mBDC), designed to overcome the biological barriers that limit the effectiveness of many cancer medicines today.

Driven by our proprietary Pentarin platform, Blend is developing cancer therapies with an unprecedented ability to penetrate deep into the cancer tissue and selectively attack the cancer cells with novel therapeutic targeting.

[Read more]